Good question. Especially since at least in the US, it is more difficult to get treated with current meds due to cost and insurance restrictions. One would hope that as data flows from this cohort, that many would be flocking at the possibility to be cured in the next cohort. Maybe the AAV8 prior exposure really is more prevalent. I do hope they release some viral load data with this cohort. Data like that could potentially boost the number of potential recruitments.
Add to My Watchlist
What is My Watchlist?